glp 1 agonist in pregnancy Glucagon-like peptide-1 receptor use pregnancy: a review glp-1 pregnancy safety news today

Description

Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)

Purity varies from 62% to 100%, and actual peptide quantity in vials can deviate by up to 260% from the advertised amount

Many reports showed that GLP-1 effects involve neural modulation and peripheral effects, which increase satiety, resting energy expenditure and lower plasma concentrations of free fatty acids [20]-[22]

Patent term restoration for top-selling drugs in the United States

Beyond their effects on glycemic control and weight loss, GLP-1 RAs are now being evaluated for a range of other conditions, including cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, knee osteoarthritis, polycystic ovary syndrome, neurodegenerative disease, and substance abuse disorders